title: [Filamentous fungal infections in immunosuppressed patients: prophylaxis and treatment].
abstract: Although the incidence of invasive aspergillosis has decreased in haematologic patients and solid organ transplant recipients due to the use of prophylaxis; aspergillosis has emerged in other populations undergoing immunosuppressive drugs where prophylaxis is not well defined presenting different clinical patterns. Voriconazole is the gold standard in the treatment of aspergillosis and probably combined therapy, with voriconazole plus anidulafungin, could have a role in the initial management of the infection.
authors.affiliation: Isabel Ruiz Camps, Unidad de Enfermedades Infecciosas. Hospital Universitari Vall d'Hebron, Barcelona, Spain. isabelruizcamps@gmail.com.
authors.forename: Isabel
authors.initials: I
authors.lastname: Ruiz-Camps
authors.forename: Maddalena
authors.initials: M
authors.lastname: Peghin
mesh_terms: D000077612:Anidulafungin; D000935:Antifungal Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D054714:Echinocandins / Q000627:therapeutic use; D005658:Fungi; D006801:Humans; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy; D009181:Mycoses / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy*; D065819:Voriconazole / Q000627:therapeutic use
chemical_list: D000935:Antifungal Agents; D004338:Drug Combinations; D054714:Echinocandins; D000077612:Anidulafungin; D065819:Voriconazole